Compare · DXCM vs IRTC
DXCM vs IRTC
Side-by-side comparison of DexCom Inc. (DXCM) and iRhythm Holdings Inc. (IRTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IRTC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 7.9x IRTC ($3.55B).
- Over the past year, DXCM is down 14.9% and IRTC is down 26.7% - DXCM leads by 11.8 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 17 for IRTC).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- iRhythm Holdings Inc.
- Price
- $72.84+0.38%
- $108.06+0.66%
- Market cap
- $28.11B
- $3.55B
- 1M return
- +20.73%
- -8.08%
- 1Y return
- -14.94%
- -26.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2016
- News (4w)
- 26
- 17
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest IRTC
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Risk Officer Shrishrimal Sumi was granted 133 shares and sold $185,652 worth of shares (1,716 units at $108.19), decreasing direct ownership by 4% to 40,287 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Rosenbaum Marc Wade was granted 178 shares and sold $78,870 worth of shares (729 units at $108.19), decreasing direct ownership by 3% to 16,155 units (SEC Form 4) to cover withholding tax
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang was granted 137 shares, increasing direct ownership by 0.25% to 55,043 units (SEC Form 4)
- CHIEF COMM & PRODUCT OFFICER Patterson Chad was granted 177 shares, increasing direct ownership by 0.30% to 58,341 units (SEC Form 4)
- EVP, Strategy & Corp Devt Freeman Sean Clinton was granted 273 shares, increasing direct ownership by 2% to 14,559 units (SEC Form 4)
- President and CEO Blackford Quentin S. was granted 178 shares, increasing direct ownership by 0.09% to 204,333 units (SEC Form 4)
- Director Bairey Merz Cathleen Noel was granted 1,573 shares, increasing direct ownership by 18% to 10,546 units (SEC Form 4)
- Director Bodaken Bruce G. was granted 1,573 shares, increasing direct ownership by 12% to 14,211 units (SEC Form 4)
- Director Ling Karen was granted 1,573 shares, increasing direct ownership by 16% to 11,141 units (SEC Form 4)